Navigation Links
Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
Date:3/10/2009

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has rescheduled its earnings call regarding its fourth quarter and year-end 2008 financial results, which was previously scheduled to be held on Thursday, March 12, 2009 at 8:30 a.m. Eastern Time, in order to complete its financial statement close and audit process. The Company will hold its conference call, issue a press release for the fourth quarter and year-ended December 31, 2008 and file its Annual Report on Form 10-K after market close on Monday, March 16, 2009.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the rescheduled call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 16.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
2. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
3. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
6. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
7. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
8. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
9. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
10. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... PMG Research is pleased to announce its participation in ... Forum in Boston on April 3-4, 2017. The CTC conference focuses on how the ... bring them closer to the patient. Clinical Trial Collaborations also will present an inaugural ...
(Date:3/27/2017)... -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, ... Welch , will be presenting at this year,s MicroCap ... at the Essex House in New York ... Mark Erlander , Ph.D., will also be available ... The presentation will be webcast live at http://wsw.com/webcast/microcapconf3/trov ...
(Date:3/27/2017)... YORK , March 27, 2017 ... developing novel therapies for neurodegenerative diseases, including Alzheimer,s ... that its application to list the Company,s common ... approved by The NASDAQ Stock Market, a unit ... the listing, Neurotrope will ring the Opening Bell at ...
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017  Infectex ... Fund (MBVF), today announced positive results of a Phase ... drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... by scientists at Sequella, Inc. ( USA ... A total of 140 patients were enrolled ...
Breaking Biology Technology:
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
Breaking Biology News(10 mins):